Optimer to Market Dificid Drug With Cubist Pharmaceuticals

Optimer Pharmaceuticals Inc. said it will co-market its fidaxomicin drug with Cubist Pharmaceuticals Inc. after winning U.S. panel backing for the antibiotic that fights a deadly bacterium often caught in hospitals.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.